Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 3 art units • 3 examiners • 0 of 4 (0%) have an AI response strategy ready
Maddon Advisors LLC manages a portfolio in the Biotechnology & Pharmaceuticals technology area with 4 pending office actions. These actions are spread across 3 distinct examiners and 3 distinct art units. This distribution indicates that the company's current patent applications cover a variety of technical sub-specialties within the pharmaceutical sector.
SHUPE, ELIZABETH A is the busiest examiner for this portfolio, currently overseeing 2 busiest examiner pending office actions. This represents half of the total 4 pending office actions for the company. The remaining actions are handled by the remaining distinct examiners, showing that SHUPE, ELIZABETH A has a higher concentration of the company's active files than her colleagues.
The fact that there are 3 distinct art units for 4 pending office actions suggests a diverse prosecution landscape. Practitioners should prepare for different examination styles across the 3 distinct examiners, though SHUPE, ELIZABETH A remains the primary point of contact with 2 busiest examiner pending actions.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 4 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SHUPE, ELIZABETH A | 2 | 66.2% | +44.2% |
| SAOUD, CHRISTINE J | 1 | 58.0% | +37.2% |
| BARRERA, IMMACULADA | 1 | 31.0% | +80.0% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17499012 | ACE2-Targeted Compositions and Methods for Treating COVID-19 | SHUPE, ELIZABETH A | 79d overdue |
| 18698856 | ACE2-Targeted Compositions and Methods for Treating COVID-19 | SHUPE, ELIZABETH A | 29d |
| 18002066 | Anti-CCR5 Monoclonal Antibody-Based Compositions and Methods | SAOUD, CHRISTINE J | 75d |
| 17996019 | ACE2-Targeted Compositions and Methods for Treating COVID-19 | BARRERA, IMMACULADA | — |
| Art Unit | Apps |
|---|---|
| 1643 | 2 |
| 1645 | 1 |
| 1671 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18698856 | ACE2-Targeted Compositions and Methods for Treating COVID-19 | SHUPE, ELIZABETH A | 1643 | §103§112DP | Final Rejection | 29d | Pending | Apr 05, 2024 |
| 18002066 | Anti-CCR5 Monoclonal Antibody-Based Compositions and Methods | SAOUD, CHRISTINE J | 1645 | §103DPOther | Non-Final OA | 75d | Pending | Dec 16, 2022 |
| 17996019 | ACE2-Targeted Compositions and Methods for Treating COVID-19 | BARRERA, IMMACULADA | 1671 | §103DPOther | Final Rejection | — | Pending | Oct 12, 2022 |
| 17499012 | ACE2-Targeted Compositions and Methods for Treating COVID-19 | SHUPE, ELIZABETH A | 1643 | §103§112DP | Non-Final OA | 79d overdue | Pending | Oct 12, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial